Recurrent Breast Cancer Recruiting Phase 2 Trials for Pertuzumab (DB06366)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

IndicationStatusPhase
DBCOND0028640 (Recurrent Breast Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01730833Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast CancerTreatment